| Name | Title | Contact Details |
|---|
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Egg Donation & Gestational Surrogacy services. Since 1996 ConceiveAbilities has professionally partnered with countless physicians and intended parents around the globe to help build families via third party reproduction. More than 20 years navigating the infertility industry has positioned ConceiveAbilities as the best partner to provide an unmatched level of service. Our unique and extensive experience and a reputation built on unparalleled service, knowledge and communication, allows us to cultivate excellent professional relationships with doctors and clinics, in addition to providing our clients, egg donors and surrogates with consistently solid service. Here at ConceiveAbilities, we believe that individuals and couples who have the desire to pursue a family, deserve the best support and resources possible. If you are committed to excellence and would like to join our team of enthusiastic dream-makers, we invite you to browse our webpage highlighting open positions among ConceiveAbilities` multiple locations.
Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive technique utilizes the company's proprietary TX MicroTip™ handpiece to cut and debride diseased tissue in an outpatient setting in under 20 minutes, using only a local anesthetic. Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures.
OneOncology is a partnership of independent community oncology practices committed to driving the future of cancer care delivery through a patient-centric, physician-driven, and technology-powered model to help improve the lives of everyone living with cancer. OneOncology empowers community oncology practices by supporting the entire continuum of care, including prevention and diagnosis, research and treatment, and long-term survivorship, palliative, and hospice care. Our technology is powered by the Flatiron suite of services to provide access to key clinical and operational data and the latest research via a cloud-based network. This comprehensive approach supports community oncologists` transition to value-based care and commitment to providing their patients with access to best-in-class healthcare, close to home. For OneOncology, cancer is personal, and the mission is critical. Working together with world class oncologists, OneOncology looks to drive the change that community cancer needs through continual learning, creative and smart evolution, and a collective desire to positively impact the lives of every person touched by cancer.
Discoveries to inspire the best life for every child and youth. The CHEO Research Institute is a not for profit corporation that connects exceptional talent and technology in pursuit of life-changing research for every child, youth and family in our community and beyond. We inspire trust in our research excellence by being curious, nimble, passionate and equitable.